2.5 or 5 mg once daily. Patient w/ moderate or severe renal impairment or end-stage renal disease requiring hemodialysis (CrCl ≤50 mL/min) & when co-administered w/ strong CYP3A4/5 inhibitors 2.5 mg once daily.
Discontinue use if serious hypersensitivity reaction or pancreatitis, severe & disabling arthralgia or bullous pemphigoid is suspected. Not to be used in type 1 DM or diabetic ketoacidosis. Heart failure. Assess renal function prior to & periodically thereafter. Concomitant use of sulfonylurea or insulin. Pregnancy & lactation. Childn <18 yr. Elderly.